Can CCL2 serum levels be used in risk stratification or to monitor treatment response in systemic sclerosis?

Annals of the Rheumatic Diseases

Volumn 67, Issue 1, 2008, Pages 105-109

  Carulli, M T ^a   Handler, C ^a   Coghlan, J G ^a   Black, C M ^a   Denton, Christopher P ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; DNA DIRECTED RNA POLYMERASE; DNA DIRECTED RNA POLYMERASE III; DNA TOPOISOMERASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PROSTACYCLIN;

ADULT; AGED; ANTIGEN ANTIBODY REACTION; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; STRATIFICATION; SYSTEMIC SCLEROSIS; TREATMENT RESPONSE; UPREGULATION;

ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHEMOKINE CCL2; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; RAYNAUD DISEASE; RISK ASSESSMENT; SCLERODERMA, DIFFUSE; SCLERODERMA, LIMITED; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

EID: 37749052490     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.067967     Document Type: Article

References (24)

1. Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. Circulation Res 2004;95:858-66.
2. Denton CP, Shiwen X, Sutton A, Abraham DJ, Black CM and Pearson JD. Scleroderma fibroblasts promote migration of mononuclear leucocytes across endothelial cell monolayers. Clin Exp Immunol 1998;114:293-300.
3. Carulli MT, Ong VH, Ponticos M, Shiwen X, Abraham DJ, Black CM, et al. Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibroblast differentiation. Arthritis Rheum 2005;52:3772-82.
4. Distler JHW, Jüngel A, Caretto D, Schulze-Horsel U, Kowal-Bielecka O, Gay RE, et al. Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells. Arthritis Rheum 2006;54:214-25.
5. Yamamoto T, Nishioka K. Role of monocyte chemoattractant protein-1 and its receptor, CCR2, in the pathogenesis of Bleomycin-induced scleroderma. J Invest Dermatol 2003;121:510-16.
6. Hasegawa M, Sato S, Takehara K. Augmented production of chemokines monocyte chemotactic protein-1 (MCP-1) macrophage inflammatory protein-1α (MIP-1α and MIP-1β) in patients with systemic sclerosis: MCP-1 and MIP-1α may be involved in the development of pulmonary fibrosis. Clin Exp Immunol 1999;117:159-65.
7. Yamamoto T, Eckes B, Hartman K, Krieg T. Expression of monocyte chemoattractant protein-1 in the lesional skin of systemic sclerosis. J Dermatol Sci 2001;26:133-9.
8. Galindo M, Santiago B, Rivero M, Rullas J, Alcami J and Pablos JL. Chemokine expression by systemic sclerosis fibroblasts. Arthritis Rheum 2001;44:1382-6.
9. Distler O, Pap T, Kowal- Bielecka O, Meyringer R, Guiducci S, Landthaler M, et al. Expression of monocyte chemoattractant protein-1 in systemic sclerosis. Arthritis Rheum 2001;44:2665-78.
10. Yamamoto T, Eckes B and Krieg T. High expression and autoinduction of monocyte chemoattractant protein-1 in scleroderma fibroblasts. Eur J Immunol 2001;31:2936-41.
11. Subcommitee for Scleroderma Criteria of the American Rheumatisnm Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
12. Ong VH, Lowri AE, Shiwen X, Fisher IB, Rajumar V, Abraham DJ, et al. Monocyte chemoattractant protein 3 as a mediator of fibrosis. Arthritis Rheum 2003;48:1979-91.
13. Valentini G, Medsger TA, Silman AJ, Bombardieri S. The assessment of patients with systemic sclerosis. Clinical Exp Rheumatology 2003;21(3 Suppl 29):S2-4.
14. Bunn CC, Denton CP, Shiwen X, Knight C, Black CM. Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol 1998;37:15-20.
15. Katsushi H, Kazufumi N, Hideki F, Katsumasa M, Hiroshi M, Kengo K, et al. Epoprostenol therapy decreases elevated circulating levels of monocyte chemoattractant protein-1 in patients with primary pulmonary hypertension. Circ J 2004;68:227-31.
16. Scala E, Pallotta S, Frezzolini A, Abeni D, Barbieri C, Sampogna F, et al. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol 2004;138:540-6.
17. Rovin BH, Lu L, Saxena R. A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Comm 1999;259:344-8.
18. Szalai C, Kozma GT, Nagy A, Bojszko A, Krikovszky D, Szabo T, et al. Polymorphism in the gene regulatory region of MCP-1 is associated with asthma susceptibility and severity. J Allergy Clin Immunol 2001;108:375-81.
19. Szalai C, Duba J, Prohaszka Z, Kalina A, Szabo T, Nagy B, et al. Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1 -2518 G/G genotype in CAD patients. Atherosclerosis 2001;158:233-9.
20. Kim HL, Lee DS, Yang SH, Lim CS, Chung JH, Kim S, et al. The polymorphism of monocyte chemoattractant protein-1 is associated with the renal disease of SLE. Am J Kidney Dis 2002;40:1146-52.
21. Karrer S, Bosserhoff AK, Weiderer P, Distler O, Landthaler M, Szeimies RM, The -2518 promotor polymorphism in the MCP-1 gene is associated with systemic sclerosis. J Invest Dermatol 2005;124:92-8.
22. Itoh T, Nagayan N, Ishibashi-ueda H, Kyotani S, Oya H, Samaki F, et al Increased plasma monocyte chemoattractant protein-1 level in idiopathic pulmonary arterial hypertension. Respirology 2006;11:158-63.
23. Ikeda Y, Yonemitsu Y, Kataoka C Kitamoto S, Yamaoka T, Nishida K, et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary hypertension in rats. Am J Physiol Heart Circ Physiol 2002;28:2021-8.
24. Williams MH, Handler CE, Akram R, Smith CJ, Das C, Smee J, et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 2006;27:1485-94.